Mallal S et al.: HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008 Feb 7;358(6):568-79.
Martin AM et al.: Immune responses to abacavir in antigen-presenting cells from hypersensitive patients. AIDS. 2007 Jun 19;21(10):1233-44
Martin AM et al.: Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4180-5.
Mallal S et al.: Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002 Mar 2;359(9308):727-32
Bundesinstitut für Arzneimittel und MedizinProdukte: Fachinformation Abacavir
http://www.ias2007.org
Interview Prof. Jürgen Rockstroh, Bonn: "PREDICT: Mehr Sicherheit bei Abacavir"
Young B et al.: First large, multiCenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America. AIDS. 2008 Aug 20;22(13):1673-5
Saag M et al.: High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis. 2008 Apr 1;46(7):1111-8